Rubio-Guerra AF

Idioma: Español
Referencias bibliográficas: 12
Paginas: 809-812
Archivo PDF: 389.04 Kb.

RESUMEN

Los antiinflamatorios no esteroides son fármacos ampliamente prescritos en la práctica médica, mientras que los efectos secundarios más frecuentes son de índole gastrointestinal, en los últimos 10 años se ha cuestionado su seguridad cardiovascular. Los inhibidores de la ciclo-oxigenasa 2 (COX 2) fueron cuestionados en su seguridad cardiovascular debido a los resultados del estudio Vioxx Gastrointestinal Outcomes Research (VIGOR). En esta revisión se analizan los resultados del estudio Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION), y sus repercusiones en las indicaciones actuales de estos fármacos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Angiolillo DJ, Weisman SM. Clinical Pharmacology and Cardiovascular Safety of Naproxen. Am J Cardiovasc Drugs 2016 Nov 8. [Epub ahead of print]. DOI:10.1007/s40256- 016-0200-5

2. Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016 Sep 28;354:i4857.

3. Castelli G, Petrone A, Xiang J, Shrader C, King D. Rates of nonsteroidal anti-inflammatory drug use in patients with established cardiovascular disease: A retrospective, crosssectional study from NHANES 2009-2010. Am J Cardiovasc Drugs 2017 Jan 6. doi: 10.1007/s40256-016-0212-1. [Epub ahead of print].

4. Pirlamarla P, Bond RM. FDA labeling of NSAIDs: review of nonsteroidal anti-inflammatory drugs in cardiovascular disease. Trends Cardiovasc Med 2016;26:675-680.

5. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528.

6. Nurmohamed MT. Therapy: Cardiovascular safety of celecoxib, naproxen and ibuprofen. Nat Rev Rheumatol 2017;13:136-138.

7. Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME. PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med 2016;375:2519-29.

8. Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther 2017;42:27-38.

9. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-1255.

10. Dentali F, Douketis JD, Woods K, Thabane L, Foster G, Holbrook A, Crowther M. Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial. Ann Pharmacother 2006;40:1241-7.

11. Ishiguro N, Hanaoka A, Okada T, Ito M. Efficacy and safety of celecoxib compared with placebo and etodolac for acute postoperative pain: a multicenter, double-blind, randomized, parallel-group, controlled trial. Nagoya J Med Sci 2015;77:81-93.

12. Schmidt M, Lamberts M, Olsen AM, Fosbøll E, Niessner A, Tamargo J, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J 2016;37:1015-23.